Peptide Therapy vs. GLP-1 Weight-Loss Treatment: What Is the Difference?
GLP-1-based medications are specific prescription therapies used for defined medical indications, while "peptide therapy" is a broad category that can include medications and compounds with very different evidence and regulatory status. Not all peptide therapies are equivalent to FDA-approved GLP-1 medications.
GLP-1-based medications
Medications such as semaglutide, tirzepatide, and liraglutide are available in FDA-approved products with indications for type 2 diabetes, chronic weight management, or both. They have been studied in large clinical trials and have detailed prescribing information.
The broader peptide category
Peptides are short chains of amino acids. Some peptide-based medications are FDA approved for specific uses, while other peptides promoted online may be investigational, unapproved, supported by limited evidence, or restricted from compounding.
Why the distinction matters
- Regulatory status differs between products
- The strength of clinical evidence differs
- Safety information and monitoring needs differ
- Compounded medications are not FDA approved
A physician evaluation helps determine whether any peptide-based or GLP-1-based treatment is appropriate for your medical history and goals.
Related pages
Talk With a Physician
Schedule a consultation with Dr. Saul Maslavi, MD to discuss your health goals, medical history, and which options may be appropriate.
Schedule An AppointmentConsultation questions: drmaslavi@peptidedoc.com
Educational information only, not medical advice. FDA approval status varies by medication and indication. Compounded medications are not FDA approved. Treatment recommendations depend on individual medical evaluation, eligibility, contraindications, and physician judgment. No dosing information is provided. PeptideDoc · Dr. Saul Maslavi, MD · 4232 Francis Lewis Boulevard, Bayside, NY 11361 · (718) 717-0003 Ext 7.